The US National Institute of Allergy and Infectious Diseases (NIAID) has expressed concerns that British drugmaker may have provided incomplete data of vaccine’s efficiency.
The speculations increased when several patients developed blood clots after jabs of the AstraZeneca COVID-19 vaccine. There are rumours that AstraZeneca may have given outdated information from the trials, resulting in an inaccurate view of the efficacy of the vaccine.
“We urge the company to work with the Data Safety Monitoring Board (DSMB) to review the efficacy data and ensure accuracy by presenting updated as quickly as possible,” said the NIAID, in a statement.
However, AstraZeneca defended the safety of the vaccine shots. The firm stated that the “safety of the vaccine has been extensively studied in Phase III of the clinical trials and peer-reviewed data confirms the vaccine has been generally well-tolerated.”
Meanwhile, several European and Scandinavian states like Denmark, Norway and Iceland temporarily suspended the use of AstraZeneca’s Covid-19 vaccine after fears of developing post-jab blood clots. Later, they resumed AstraZeneca vaccinations after The European Medicines Agency (EMA) rebutted the assumption by stating that there “no chances of developing blood clots after using AstraZeneca vaccination.”
In September 2020, AstraZeneca had suspended global trials of its experimental coronavirus vaccine after an unexplained illness in a participant in Britain.
The vaccine had been described by the World Health Organization as probably the world’s leading candidate and the furthest developed.